AU2002309583A1 - Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer - Google Patents

Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer

Info

Publication number
AU2002309583A1
AU2002309583A1 AU2002309583A AU2002309583A AU2002309583A1 AU 2002309583 A1 AU2002309583 A1 AU 2002309583A1 AU 2002309583 A AU2002309583 A AU 2002309583A AU 2002309583 A AU2002309583 A AU 2002309583A AU 2002309583 A1 AU2002309583 A1 AU 2002309583A1
Authority
AU
Australia
Prior art keywords
methods
lung cancer
modulators
diagnosis
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002309583A
Inventor
Natasha Aziz
Richard Murray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of AU2002309583A1 publication Critical patent/AU2002309583A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
AU2002309583A 2001-04-18 2002-04-18 Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer Abandoned AU2002309583A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US28477001P 2001-04-18 2001-04-18
US60/284,770 2001-04-18
US29049201P 2001-05-10 2001-05-10
US60/290,492 2001-05-10
US33924501P 2001-11-09 2001-11-09
US60/339,245 2001-11-09
US35066601P 2001-11-13 2001-11-13
US60/350,666 2001-11-13
US33437001P 2001-11-29 2001-11-29
US60/334,370 2001-11-29
US37224602P 2002-04-12 2002-04-12
US60/372,246 2002-04-12
PCT/US2002/012476 WO2002086443A2 (en) 2001-04-18 2002-04-18 Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer

Publications (1)

Publication Number Publication Date
AU2002309583A1 true AU2002309583A1 (en) 2002-11-05

Family

ID=27559574

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002309583A Abandoned AU2002309583A1 (en) 2001-04-18 2002-04-18 Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer

Country Status (5)

Country Link
EP (1) EP1463928A2 (en)
JP (1) JP2005527180A (en)
AU (1) AU2002309583A1 (en)
CA (1) CA2444691A1 (en)
WO (1) WO2002086443A2 (en)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2075253A1 (en) * 2000-06-23 2009-07-01 Genentech, Inc. Compositions and methds for the diagnosis and treatment of disorders involving angiogensis
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US7265210B2 (en) 2000-09-15 2007-09-04 Genentech, Inc. Anti-PRO9821 antibodies
AU2002226079A1 (en) 2000-12-08 2002-06-18 Curagen Corporation Method of detecting and treating tuberous sclerosis complex associated disorders
US20060035237A1 (en) * 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
WO2002099060A2 (en) * 2001-06-05 2002-12-12 Exelixis, Inc. Dgks as modifiers of the p53 pathway and methods of use
EP1444361A4 (en) * 2001-09-28 2006-12-27 Whitehead Biomedical Inst Classification of lung carcinomas using gene expression analysis
AU2002359697A1 (en) * 2001-12-20 2003-07-09 Tularik Inc. Identification of an amplified gene and target for drug intervention
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
DE10225144A1 (en) * 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh Tumor-associated peptides binding to MHC molecules
EP1552845A4 (en) * 2002-06-26 2006-06-07 Takeda Pharmaceutical Preventives/remedies for cancer
GB0215224D0 (en) * 2002-07-01 2002-08-14 Inpharmatica Ltd Protein
WO2004020668A2 (en) * 2002-08-30 2004-03-11 Oncotherapy Science, Inc. Method for treating synovial sarcoma
US7803370B2 (en) 2002-08-30 2010-09-28 Oncotherapy Science, Inc. Method for treating synovial sarcoma
WO2004024063A2 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
JP2006515515A (en) * 2002-12-20 2006-06-01 アバロン ファーマシューティカルズ，インコーポレイテッド Amplified cancer target genes useful for diagnostic and therapeutic screening
AU2003292737A1 (en) * 2002-12-24 2004-07-22 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
CA2511522A1 (en) * 2002-12-26 2004-07-15 Takeda Pharmaceutical Company Limited Novel proteins and use thereof
US20070026398A1 (en) * 2003-03-03 2007-02-01 Farnsworth Amanda L Protein tyrosine phosphatase-prl-1 a a marker and therapeutic target for pancreatic cancer
EP1601971A1 (en) * 2003-03-11 2005-12-07 The University Of British Columbia Diagnosis of gynecological neoplasms by detecting the levels of oviduct-specific glycoprotein
CA2520512A1 (en) * 2003-03-24 2004-10-07 Corixa Corporation Methods, compositions and kits for the detection and monitoring of lung cancer
AU2003901511A0 (en) * 2003-03-28 2003-04-17 Bionomics Limited Nucleic acid molecules associated with angiogenesis II
EP1619499B1 (en) 2003-04-25 2011-01-05 Takeda Pharmaceutical Company Limited Novel screening method
WO2004097034A2 (en) * 2003-05-02 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 4 (tmprss4)
EP1633892A4 (en) * 2003-06-10 2007-10-24 Univ Boston Detection methods for disorders of the lung
WO2004111197A2 (en) * 2003-06-10 2004-12-23 Trustees Of Boston University Gene expression signatures, methods and compositions for diagnosing disorders of the lung
WO2005002417A2 (en) * 2003-06-20 2005-01-13 Avalon Pharmaceuticals, Inc. Cancer -linked gene aas target for chemotherapy
CN105316405A (en) * 2003-07-17 2016-02-10 环太平洋生物技术有限公司 Markers for detection of gastric cancer
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005059109A2 (en) * 2003-12-15 2005-06-30 The Regents Of The University Of California Molecular signature of the pten tumor suppressor
CA2555509A1 (en) * 2004-01-27 2005-07-27 Compugen Usa, Inc. Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer
EP1584684A1 (en) 2004-02-20 2005-10-12 Samsung Electronics Co., Ltd. Breast cancer related protein, gene encoding the same, and method of diagnosing breast cancer using the protein and gene
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US7399469B2 (en) * 2004-03-26 2008-07-15 Pdl Biopharma, Inc. Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer
JP2005314397A (en) * 2004-03-31 2005-11-10 Mitsubishi Chemicals Corp Anti-chondromodulin-1-specific antibody and its use
WO2005103283A1 (en) 2004-04-23 2005-11-03 Takeda Pharmaceutical Company Limited Novel method of screening
DE102004023187A1 (en) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
JPWO2005118631A1 (en) 2004-06-03 2008-05-29 武田薬品工業株式会社 Novel protein complex and its use
CA2579558A1 (en) * 2004-09-08 2006-03-16 Ludwig Institute For Cancer Research Cancer-testis antigens
AU2005286607B2 (en) 2004-09-23 2011-01-27 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
ATE451619T1 (en) * 2004-10-19 2009-12-15 Onco Therapy Science Inc PKP3 ONCOGEN AS A PROGNOSTIC INDICATOR FOR LUNG ADENOCARCINOMA
EP1846550A2 (en) * 2005-02-10 2007-10-24 Centre National De La Recherche Scientifique (Cnrs) Use of the mcm8 gene for the preparation of a pharmaceutical composition
EP1853703B1 (en) 2005-02-25 2011-04-13 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing ttk polypeptides
DE102005013846A1 (en) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
EP2360279A1 (en) 2005-04-14 2011-08-24 Trustees Of Boston University Diagnostic for lung disorders using class prediction
GB0508863D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Peptide
EP1888634A2 (en) * 2005-05-13 2008-02-20 Oxford Biomedica (UK) Limited Mhc class i and ii peptide antigens derived from tumour antigen 5t4
WO2007067730A2 (en) 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
GB0526498D0 (en) * 2005-12-28 2006-02-08 Randox Lab Ltd Method
WO2007103541A2 (en) 2006-03-09 2007-09-13 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
ES2544957T3 (en) 2006-03-21 2015-09-07 Genentech, Inc. Combined therapy involving alpha5beta1 antagonists
JP5298266B2 (en) * 2006-03-31 2013-09-25 静岡県 Evaluation kit for small cell lung cancer
JP5114637B2 (en) * 2006-03-31 2013-01-09 静岡県 Determination method of small cell lung cancer
ES2405618T3 (en) 2006-06-21 2013-05-31 Oncotherapy Science, Inc. Monoclonal antibodies directed to tumors for FZD10 and uses thereof
CA2655933C (en) * 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
JP5317697B2 (en) 2006-08-14 2013-10-16 中外製薬株式会社 Diagnosis and treatment of cancer using anti-Desmoglein3 antibody
EP1932854A1 (en) * 2006-12-15 2008-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lysosomal associated membrane protein (LAMP) - like polypeptide, ligands to the same, and use of the same in the frame of detection and purification of human plasmacytoid dendritic cells
TWI494319B (en) * 2007-02-21 2015-08-01 Oncotherapy Science Inc Peptide vaccines for cancers expressing tumor-associated antigens
WO2008140774A2 (en) 2007-05-08 2008-11-20 Picobella Llc Methods for diagnosing and treating prostate and lung cancer
WO2008153814A2 (en) * 2007-05-29 2008-12-18 President And Fellows Of Harvard College Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
WO2009017833A2 (en) 2007-08-02 2009-02-05 Arresto Biosciences Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
BRPI0816236A2 (en) 2007-08-20 2015-08-18 Oncotherapy Science Inc Cdh3 peptide and medicinal agent containing the same
JP2010536367A (en) * 2007-08-24 2010-12-02 オンコセラピー・サイエンス株式会社 Cancer-related genes, CDCA5, EPHA7, STK31 and WDHD1
CA2736170A1 (en) * 2007-09-06 2009-03-12 Case Western Reserve University Methods for diagnosing and treating cancers
EP2193211A4 (en) 2007-09-19 2010-12-08 Univ Boston Identification of novel pathways for drug development for lung disease
AR066170A1 (en) 2007-09-26 2009-07-29 Genentech Inc ANTI INTEGRINA ALFA 5 BETA 1
AR072804A1 (en) 2008-07-15 2010-09-22 Genentech Inc CONJUGATES DERIVED FROM ANTHRACICLINE, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE AS ANTITUMOR AGENTS.
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
CN104198709A (en) * 2008-09-09 2014-12-10 私募蛋白质体公司 Lung cancer biomarkers and uses thereof
WO2010037124A1 (en) 2008-09-29 2010-04-01 The Trustees Of The University Of Pennsylvania Tumor vascular marker-targeted vaccines
JP5663790B2 (en) 2008-10-22 2015-02-04 オンコセラピー・サイエンス株式会社 RAB6KIFL / KIF20A epitope peptide and vaccine containing the same
WO2010047028A1 (en) * 2008-10-24 2010-04-29 Oncotherapy Science, Inc. Screening method of anti-lung or esophageal cancer compounds
CA3050455A1 (en) 2008-11-03 2010-06-03 Adc Therapeutics Sa Antibodies that specifically block the biological activity of a tumor antigen
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
WO2010095461A1 (en) * 2009-02-20 2010-08-26 国立大学法人東京大学 Novel monoclonal antibody, and use thereof
JP6051048B2 (en) 2009-03-25 2016-12-21 ジェネンテック， インコーポレイテッド Novel anti-α5β1 antibody and use thereof
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
SG178845A1 (en) 2009-08-21 2012-04-27 Gilead Biologics Inc Catalytic domains from lysyl oxidase and loxl2
US8470980B2 (en) 2009-09-09 2013-06-25 Centrose, Llc Extracellular targeted drug conjugates
US20120322075A1 (en) * 2009-10-26 2012-12-20 Externautics S.P.A. Lung Tumor Markers and Methods of Use Thereof
WO2011051280A1 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Ovary tumor markers and methods of use thereof
WO2011051271A2 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Prostate tumor markers and methods of use thereof
US9745589B2 (en) 2010-01-14 2017-08-29 Cornell University Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
DK2528625T3 (en) 2010-04-15 2013-10-14 Spirogen Sarl Pyrrolobenzodiazepines and their conjugates
CN114246952A (en) 2010-06-08 2022-03-29 基因泰克公司 Cysteine engineered antibodies and conjugates
SG10201508656VA (en) * 2010-07-09 2015-11-27 Somalogic Inc Lung cancer biomarkers and uses thereof
MX341517B (en) 2010-08-13 2016-08-24 Somalogic Inc Pancreatic cancer biomarkers and uses thereof.
AU2011312417B2 (en) 2010-09-29 2015-08-20 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
PT3173427T (en) 2011-03-31 2019-09-17 Adc Therapeutics Sa Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
ES2567276T3 (en) 2011-05-12 2016-04-21 Genentech, Inc. LC-MS / MS method of monitoring multiple reactions to detect therapeutic antibodies in animal samples using frame-changing peptides
CN103987407B (en) 2011-10-14 2016-08-24 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and conjugate thereof
NZ625758A (en) 2012-01-09 2016-05-27 Alethia Biotherapeutics Inc Method for treating breast cancer
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
HUE039329T2 (en) 2012-10-12 2018-12-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
MX364327B (en) 2012-10-12 2019-04-23 Medimmune Ltd Pyrrolobenzodiazepine-anti-cd22 antibody conjugates.
ES2660029T3 (en) 2012-10-12 2018-03-20 Medimmune Limited Antibody-pyrrolobenzodiazepine conjugates
ES2680153T3 (en) 2012-10-12 2018-09-04 Adc Therapeutics Sa Anti-PSMA-pyrrolobenzodiazepine antibody conjugates
CA2885340C (en) 2012-10-12 2016-11-08 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
RS57694B1 (en) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
JP6392763B2 (en) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ Pyrrolobenzodiazepine-antibody conjugate
ES2658888T5 (en) 2012-12-21 2021-10-19 Medimmune Ltd Pyrrolobenzodiazepines and their conjugates
WO2014096365A1 (en) 2012-12-21 2014-06-26 Spirogen Sàrl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP6340019B2 (en) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugates
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
WO2014186036A1 (en) 2013-03-14 2014-11-20 Allegro Diagnostics Corp. Methods for evaluating copd status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
EA201690195A1 (en) 2013-08-12 2016-05-31 Дженентек, Инк. ANTIBODY CONJUGATE CONNECTIONS ON THE BASIS OF DIMER 1- (HLORMETHYL) -2,3-DIGYDRO-1H-BENZO [E] INDOL AND METHODS OF APPLICATION AND TREATMENT
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
JP6980384B2 (en) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド 1- (Chloromethyl) -2,3-dihydro-1H-benzo [E] indole dimer antibody-drug conjugate compound, and methods of use and treatment
PE20161394A1 (en) 2013-12-16 2017-01-06 Genentech Inc PEPTIDOMIMETIC COMPOUNDS AND THEIR ANTIBODY-DRUG CONJUGATES
MX371092B (en) 2013-12-16 2020-01-16 Genentech Inc Peptidomimetic compounds and antibody-drug conjugates thereof.
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3191134B1 (en) 2014-09-12 2019-11-20 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
BR112017003236A2 (en) 2014-09-12 2017-11-28 Genentech Inc cysteine engineered antibodies, drug conjugates and antibodies, drug and antibody conjugate preparation method and pharmaceutical composition
CR20170099A (en) 2014-09-17 2017-07-19 Genentech Inc PIRROLOBENZODIAZEPINAS AND CONJUGADOS DE ANTIBERPOS-DISULFURO DE LAS SISAS
CN114606309A (en) 2014-11-05 2022-06-10 威拉赛特公司 Diagnostic system and method using machine learning and high-dimensional transcription data
MX2017006770A (en) 2014-11-25 2018-02-09 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates.
EP3226909A1 (en) 2014-12-03 2017-10-11 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
MY193703A (en) 2015-03-27 2022-10-26 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various tumors
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP2019522633A (en) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド PROTAC antibody conjugates and methods of use
CN109313200B (en) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 Bioanalytical methods for characterizing site-specific antibody-drug conjugates
WO2017214024A1 (en) 2016-06-06 2017-12-14 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
TWI762516B (en) 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 Monoclonal antibodies against FZD10 and their uses
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
TW201839136A (en) 2017-02-06 2018-11-01 瑞士商諾華公司 Compositions and methods for the treatment of hemoglobinopathies
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
PT3544636T (en) 2017-02-08 2021-05-04 Medimmune Ltd Pyrrolobenzodiazepine-antibody conjugates
WO2018192944A1 (en) 2017-04-18 2018-10-25 Medimmune Limited Pyrrolobenzodiazepine conjugates
KR20190141666A (en) 2017-04-20 2019-12-24 에이디씨 테라퓨틱스 에스에이 Combination Therapy with Anti-AXL Antibody-Drug Conjugates
AU2018285562B2 (en) 2017-06-14 2024-01-18 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
ES2906965T3 (en) 2017-08-18 2022-04-21 Medimmune Ltd Pyrrolobenzodiazepine conjugates
WO2019060398A1 (en) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
TW202037381A (en) 2018-10-24 2020-10-16 瑞士商赫孚孟拉羅股份公司 Conjugated chemical inducers of degradation and methods of use
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN114163513A (en) * 2021-03-24 2022-03-11 深圳市新靶向生物科技有限公司 Antigenic peptide combination related to liver cancer driver gene mutation and application thereof
EP4294951A1 (en) * 2022-05-13 2023-12-27 Hummingbird Diagnostics GmbH Novel rna molecule for cancer detection

Also Published As

Publication number Publication date
WO2002086443A2 (en) 2002-10-31
JP2005527180A (en) 2005-09-15
CA2444691A1 (en) 2002-10-31
EP1463928A2 (en) 2004-10-06
WO2002086443A8 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
AU2002309583A1 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2002245317A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
AU2002330039A1 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
AU2002347428A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2002068677A8 (en) Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
AU2002257004A1 (en) Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
AU2002215345A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
AU2002251841A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2002339865A1 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
AU2002251844A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001231199A1 (en) Compositions and methods for the early diagnosis of ovarian cancer
AU2001261007A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002311909A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002249871A1 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
AU2002218770A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003022987A9 (en) Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
AU2002254482A1 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
AU2001290902A1 (en) Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
AU3755300A (en) Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
AU2002359330A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002364708A1 (en) Novel compositions and methods for cancer
AU2001259062A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002239431A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase